Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12393190 | 0.87 | CTSK (0.46) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12393191 | 0.82 | CTSK (0.44) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL16508865 | 0.81 | FAAH (0.43) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL15216070 | 0.79 | FAAH (0.47) | CTSK | |
| SCHEMBL6524090 | 0.79 | CTSK (0.42) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12228047 | 0.79 | CTSK (0.42) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14464620 | 0.79 | CTSK (0.42) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2579949 | 0.79 | CTSK (0.44) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8586908 | 0.78 | CHRM2 (0.41) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL313041 | 0.77 | CTSK (0.44) | CTSKCHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643706-B1 | MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES | EISAI R&D MAN CO LTD (JP) | 2023-11-15 | — | — | EP | claimed |
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| US-7943758-B2 | 3′-end nucleoside unit comprising phosphoramidite | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-05-17 | — | — | US | claimed |
| US-20080039620-A1 | 3'-End Nucleoside Unit Comprising Phosphoramidite | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-02-14 | — | — | US | claimed |
| EP-1719778-A1 | 3'-TERMINAL NUCLEOSIDE UNIT CONTAINING PHOSPHORAMIDITE | Japan Science and Technology Agency (JP) | 2006-11-08 | — | — | EP | claimed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4396354-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024130217-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130218-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240174710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-20240175016-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-7569685-B2 | Artificial RNAóS modified at the 2ó-hydroxyl group | JAPAN SCIENCCE AND TECHNOLOGY AGENCY (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-2006293-A9 | 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-2006293-A2 | 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE | Tokyo Institute of Technology (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20080039620-A1 | 3'-End Nucleoside Unit Comprising Phosphoramidite | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080021206-A1 | Novel Artificial Rnaos Modified At The 2o-Hydroxyl Group | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1726597-A1 | NOVEL ARTIFICIAL RNAóS MODIFIED AT THE 2ó-HYDROXYL GROUP | Japan Science and Technology Agency (JP) | 2006-11-29 | — | — | EP | disclosed |
| EP-1719778-A1 | 3'-TERMINAL NUCLEOSIDE UNIT CONTAINING PHOSPHORAMIDITE | Japan Science and Technology Agency (JP) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006065751-A2 | CPG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021206-A1 | Novel Artificial Rnaos Modified At The 2o-Hydroxyl Group | FBL, NSUN2, METTL16 | CTSK 4382/4885CHRM2 1626/4885CHRM4 2350/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | CTSK 4824/4885CHRM2 3933/4885CHRM4 2410/4885 |
| US-20080039620-A1 | 3'-End Nucleoside Unit Comprising Phosphoramidite | POLR2H, POLN, RNGTT | CTSK 4825/4885CHRM2 3208/4885CHRM4 2771/4885 |
| US-20240174710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | ALKBH1, DUT, RNGTT | CTSK 3540/4885CHRM2 4024/4885CHRM4 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.